Banner
Home → Focus

Focus
Genesis Healthcare Settlement Another Example of Government's Anti-Fraud Campaign Print E-mail
Written by Vitale Health Law   
Tuesday, 27 June 2017 00:00

Whatever else is taking place in the nation's capital these days, one thing is for certain, there is no letup in the government's crackdown on healthcare fraud. This is made  clear by the continued announcements of multimillion-dollar settlements coming from various fraud-fighting agencies.

One of the more recent settlements involves Genesis Healthcare, Inc., a Kennett Square, Pa. provider of short-term post-acute, rehabilitation, skilled nursing and long-term care services.

Earlier this month, the U.S. Department of Justice announced that Genesis will pay the federal government $53.6 million, including interest, to settle six federal lawsuits and investigations regarding the submission of false claims for medically unnecessary therapy and hospital services, as well as "grossly substandard" nursing home care.

The settlement resolved four sets of allegations...

Read More

Last Updated on Monday, 24 July 2017 16:59
 
Florida Supreme Court Overturns Med Mal Damage Awards Cap Print E-mail
Written by Matt Gracey   
Wednesday, 21 June 2017 00:00

The Florida Supreme Court's recent overturn of the caps on non-economic damage awards in medical malpractice cases is the final nail in the coffin of tort reforms enacted in 2003. The frequency of lawsuits against doctors and correspondingly the premiums for malpractice insurance in Florida since 2003 have dropped on average about 65%. The market has become healthy with many insurers competing for doctors' business. As the premiums have steadily dropped over the last decade and a half, many insurers' loss ratios have now increased up to, and in many cases over, the 100% combined loss ratio mark. Thus, most insurers have been needing rate increases to stop mounting losses or thin profit margins. This court action will hasten the anticipated hardening of the marketplace and doctors are sure to see higher prices for their coverage and fewer insurers bidding on their malpractice insurance in the near future.

Five Steps I Recommend to Florida Doctors Now...

Read More

Last Updated on Friday, 23 June 2017 17:01
 
Steve Scalise's Doctor On Congressman's Condition, Injuries Sustained Print E-mail
Written by FHI's Week in Review   
Monday, 19 June 2017 17:53

Dr. John Torres has an exclusive interview with Dr. Jack Sava (director of trauma at the MedStar Washington Hospital Center) about Rep. Steve Scalise's condition, what's being done to treat him and Scalise's chances for recovery. This video was posted to YouTube by NBC on 6.16.17...

Read more in the current issue of Week in Review>> http://conta.cc/2tFbWdB

Last Updated on Tuesday, 20 June 2017 13:47
 
NEJM Offers Bleak Assessment of Global Obesity Situation Print E-mail
Written by Jeffrey Herschler   
Friday, 16 June 2017 16:48

Entitled Health Effects of Overweight and Obesity in 195 Countries over 25 Years and posted to the New England Journal of Medicine on 6.12.17, the authors offered the following depressing statistics and insights:
  • The prevalence of obesity among children and adults has doubled in 73 countries since 1980 and has shown a continuous increase in most other countries.
  • Epidemiologic studies have identified high body-mass index as a risk factor for an expanding set of chronic diseases.
  • In 2015, high BMI contributed to 4.0 million deaths, which represented 7.1% of the deaths from any cause.
In recent years, some countries have started to implement a range of interventions to reduce obesity, but no major population success has yet been shown.

Last Updated on Tuesday, 20 June 2017 13:45
 
FDA Approves First Generic Truvada in U.S. Print E-mail
Written by FHI's Week in Review   
Sunday, 11 June 2017 15:30

Robert Lowes delivers news (login/complimentary subscription required) from the FDA on June 09, 2017:

The U.S. Food and Drug Administration (FDA) has approved the first generic version of emtricitabine/tenofovir disoproxil (Truvada, Gilead Sciences) to both treat and prevent HIV infections in this country, the agency announced today.

According to Mr. Lowes:

The list price for Gilead Science's Truvada is roughly $1500 for a month's regimen of one pill per day, or about $18,000 a year, although health insurance and patient-assistance programs knock down the price considerably. Generic versions of Truvada in other countries cost as little as $70 a year, according to Mitchell Warren, executive director of AVAC, an international organization that promotes HIV prevention.

Read more in the current issue of Week in Review>> http://conta.cc/2tdyFgW

Last Updated on Monday, 12 June 2017 15:34
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 5 of 112


Banner
Website design, development, and hosting provided by
Netphiles